
    
      This study is designed to evaluate the efficacy and safety of icotinib and pemetrexed-based
      first-line induction and maintenance chemotherapy in advanced lung adenocarcinoma with
      EGFR-mutation，primary endpoint is progress-free survival，second endpoints include overall
      survival, time to progression, and so on.
    
  